Estrategia en Cáncer del Sistema Nacional de Salud

Objectives

Spain’s National Health System Cancer Strategy provides a national, evidence-based framework to improve cancer prevention, early detection, diagnosis, treatment, survivorship, palliative care, information and research, guided by quality, equity and territorial cohesion.[1][2][3]It seeks to reduce the population burden of cancer and geographical and socioeconomic inequalities, while improving outcomes and quality of life across the full care pathway.[4][5][6]

• Promote health and prevent cancer by addressing tobacco, alcohol, unhealthy diet, physical inactivity, obesity, ultraviolet radiation, occupational carcinogens, radon and infection-related risks.[7][8][9][10][11][12]
• Expand organised, population-based screening for breast, cervical and colorectal cancer, while avoiding routine screening for other cancers unless effectiveness and health impact, including harms, are demonstrated.[13][14][15]
• Achieve vaccination coverage of at least 95% for three-dose hepatitis B vaccination at 12 months and at least 80% for complete human papillomavirus vaccination at age 15.[13][16]
• Improve rapid diagnosis and equitable treatment access, including multidisciplinary care, reference centres for rare tumours and complex procedures, molecular diagnosis, precision oncology, radiotherapy and clinically valuable therapies.[17][18][19][20][21]
• Strengthen person-centred care by integrating psychological, social, nutritional, rehabilitation, fertility-preservation, survivorship and palliative-care support for patients, families and carers.[22][23][24][6][25]
• Concentrate childhood and adolescent cancer care in specialised paediatric onco-haematology units, support age-appropriate transition to adult services, and improve long-term follow-up for late effects and second primary cancers.[26][27][28][29]
• Strengthen cancer registries, data systems, outcome evaluation and basic, translational, clinical and health-services research.[30][31][32][33]

Implementation

Implementation relies on inter-territorial governance, with the Interterritorial Council of the National Health System approving the Strategy and autonomous communities leading delivery within a common national framework.[34][1][35]Development and follow-up involve institutional and technical committees including autonomous communities, the Ministry of Health, the Carlos III Health Institute, professional societies, patient organisations, researchers and expert contributors.[34][36][3]

• Deliver prevention through a Health in All Policies approach spanning health, labour, education, urban planning, environment, transport, families and communities, with interventions adapted to population needs and supported by citizen participation.[37][38][39]
• Operate breast, cervical and colorectal screening as organised programmes that identify and invite eligible populations, conduct testing, investigate positive results, treat diagnosed cases and apply quality assurance throughout the pathway.[40][41]Cervical screening is to move from opportunistic to population-based provision, with programme initiation before 2024 and full invitation coverage before 2029.[14][42]
• Organise cancer care through multidisciplinary tumour units or committees with defined membership, documented therapeutic decisions, clinical protocols, case-management or nursing coordination, patient information, referral routes, follow-up arrangements and access to clinical trials.[20][43][44]
• Build tiered care networks connecting primary care, local and regional hospitals, autonomous-community reference centres, National Health System Centres, Services and Reference Units, and European Reference Networks.[45][44][46]Concentrate rare tumours and highly complex procedures in accredited reference units with minimum activity thresholds, while enabling locally delivered non-complex care where appropriate.[47][48][20]
• Establish rapid diagnostic pathways for common cancers, with median targets of 7 days from primary-care referral to first hospital assessment, 15 days to pathological confirmation or exclusion, and 4 weeks for complete diagnosis where molecular testing is required.[45][49][50]Target treatment initiation within median intervals of 2 weeks for surgery, 1 week for systemic treatment and 4 weeks for radiotherapy, including planning.[45][50]
• Implement precision oncology through equitable access to clinically relevant genetic and biomarker testing, quality-assured pathology, expert double reading for rare tumours, and a nationally agreed organisational model whose financing arrangements remain undefined.[18][51][21]
• Coordinate childhood and adolescent care through regional committees, designated units, tumour committees, unified protocols, multidisciplinary teams, network arrangements and cross-community referral where local case volumes are insufficient.[52][29][53][54]
• Monitor performance through indicators drawn from National Health System information systems, autonomous communities, cancer registries, population surveys, hospital records, audits and specialised programmes.[55][56][57]Key measures include prevention risks, vaccination, screening coverage and participation, diagnostic and treatment timeliness, multidisciplinary review, survival, incidence, mortality, clinical outcomes, registry coverage and research activity.[58][59][60][61][62]
• Evaluate implementation continuously using agreed indicators and questionnaires, with annual screening-programme evaluation reports and audits of care processes where specified.[55][63][60]The supplied material does not specify an overall Strategy budget, financing allocation or quantified resource-mobilisation plan.[31][55]

Monitoring & Evaluation

The strategy establishes a broad monitoring and evaluation architecture spanning prevention, screening, care quality, cancer outcomes, survivorship, paediatric services, information systems and research. Evaluation is intended as a systematic, continuous process that produces scientifically valid and useful information for decision-making, drawing on National Health System information systems, autonomous communities, population surveys, cancer registries, hospital data and occupational-health sources.[55][56][64]

• Monitor population outcomes through cancer incidence, mortality, premature mortality, potential years of life lost, prevalence, observed and net survival, and childhood-cancer incidence and follow-up. Indicators are generally disaggregated by sex, age, tumour type and, where available, autonomous community.[58][65][61][66][62][67]
• Strengthen population-based cancer registration and data quality. Consolidated adult registries cover 27% of Spain’s population, with potential coverage of 53% if all existing registries are consolidated; the childhood registry reports 94% national coverage.[30][68]
• Track prevention indicators including diet, obesity, sedentary behaviour, alcohol and tobacco use, asbestos exposure, occupational and radon-attributable cancer burden, and hepatitis B and human papillomavirus vaccination coverage.[56][64][59][69][16]
• Assess vaccination against explicit targets of at least 95% three-dose hepatitis B coverage at 12 months and at least 80% complete human papillomavirus vaccination at age 15 in every autonomous community.[13][16]
• Evaluate organised breast, cervical and colorectal screening through invitation coverage, participation, test completion, positivity, detection of cancer and high-risk adenomas, and annual programme reports. Minimum participation targets are 70% for breast and cervical screening and 65% for colorectal screening; information systems in every autonomous community and autonomous city are expected to support integrated management and evaluation.[13][14][57][70][71][72][63]
• Monitor diagnostic and treatment timeliness through targets of seven calendar days from primary-care referral to hospital assessment, 15 days from assessment to pathological confirmation or exclusion, four weeks for complete diagnosis requiring molecular testing, two weeks to surgery, one week to systemic treatment and four weeks to radiotherapy.[45][49][73][74][50][60]
• Assess cancer-service quality through multidisciplinary tumour committee coverage, documented therapeutic decisions, reference-unit activity thresholds, care-network models, radiotherapy resource mapping, pathological quality assurance and outcome audits. The indicative target is 100% multidisciplinary assessment for relevant cancer patients.[20][44][75][46][60][76]
• Require hospitals to assess clinical outcomes, including stage-specific survival, recurrence and 30-day or same-admission surgical mortality, and feed findings back to clinical teams and tumour committees for improvement.[77]
• Measure patient-centred care through emotional-distress screening, fertility-preservation referral, social-care plans, survivorship plans and coordinated primary-to-hospital follow-up. Several indicators carry an indicative 100% standard.[78][79][80][81][82]
• Monitor paediatric and adolescent cancer care through regional coordination committees, designated paediatric onco-haematology units, tumour committees, network protocols, activity records, research participation and cross-community referrals. Designated units are expected to treat more than 30 new patients annually, and many organisational indicators use 100% orientative standards.[52][29][83][84][53][85]
• Track cancer research through the share and average value of cancer projects funded by the Carlos III Health Institute, cancer’s priority status in health-research calls, non-commercial clinical trials, coordinated multicentre projects, institute priorities and scientific publications.[86][33][87][88][89][90]

Accountability is distributed across the Ministry of Health, autonomous communities, the National Institute of Health Management, hospitals, registries and the Carlos III Health Institute, using audits, annual reports, studies and indicator-based assessment.[91][92][72][44][60]The supplied material does not set out a single consolidated reporting calendar, sanctions regime or overarching accountability framework for all strategic lines.[93][15][55]

Costing & Financing

The strategy identifies significant resource pressures and financing needs, but does not provide a consolidated implementation budget, costed action plan, quantified funding gap or resource-mobilisation framework.[19][94][95][55]

• Recognise insufficient financing for cancer research projects and limited financing for the Spanish Clinical Research Network, while identifying the Carlos III Health Institute, autonomous communities and non-profit organisations as important research funders.[96][97][31][32]
• Address the absence of defined financing arrangements for precision oncology, despite requirements for biomarker testing, quality assurance, specialist expertise, technology and equitable access.[18][51][98]
• Manage increasing treatment costs, which are described as rising faster than treatment costs for most other conditions, by assessing therapeutic innovation in relation to clinical benefit, toxicity, survival, quality of life and financial sustainability.[94][95]
• Consider cost-effectiveness, resource requirements, feasibility, diagnostic-assessment costs and screening frequency when assessing potential lung-cancer screening models.[99][100]Colorectal screening is characterised as among the most cost-effective screening interventions because early detection may reduce incidence-related costs.[101]
• Recognise that smoking-cessation programmes delivered through the health system are cost-effective and that tobacco use creates direct costs from mortality and morbidity as well as indirect productivity and social costs.[102][9]
• Use the Health Cohesion Fund to compensate designated reference units for highly specialised care provided to patients referred from other autonomous communities, without a stated monetary amount.[103]
• Estimate the healthcare cost of work-attributable cancer and the burden attributable to occupational exposures and radon, although no estimates are provided.[104][69]
• Recognise financial pressures on patients and families, including income loss and additional costs for transport, medicines and hair prostheses, and the need for sufficient psychological and social-care resources.[105][106]

Specific programme budgets, allocations, unit costs, funding sources and economic assumptions are not specified for most prevention, screening, care-network, radiotherapy, palliative-care, registry or survivorship measures.[40][19][6][30][20]